Abstract
Introduction Genome Wide Association Studies (GWAS) revealed the highly polygenic architecture of Attention-Deficit/Hyperactivity Disorder (ADHD) and highlighted the contribution of common variants related to brain development and function. In parallel, several imaging studies attempted to discover disorder-related brain structures, with some significant findings concerning white matter. Two-sample mendelian randomization (2SMR) is a powerful tool to evaluate causality between two phenotypes using summary statistics data. We aimed to investigate a possible causal relationship between white matter genetically predicted variation and ADHD diagnosis through 2SMR.
Methods A unidirectional two-sample MR analysis was performed based on summary statistics of GWAS between 22 different white matter (WM) mean fractional anisotropy measures and ADHD. We used 4 different MR approaches, considering IVW random effects as the main analysis, followed by several sensitivity analyses. Linkage Disequilibrium Score Regression (LDSC) was evaluated in the same set of samples to corroborate the direction of associations.
Results and Discussion Our most consistent finding across MR and LDSC approach, following the sensitivity analyses, indicate that the decreased WM microstructure integrity of the fornix stria terminalis (FXSTivw beta:-0.266 SE:0.083 pFDR: 0.021) genetic liability has a causal influence on ADHD diagnosis. The FXST is formed by connection fibers inside the limbic system, which is crucial to emotional processing, learning, and memory, functions usually impaired in ADHD. Therefore, this study increases knowledge concerning ADHD neurobiology and provides novel evidence of the causal effect of WM integrity in the limbic system, which could contribute to the advances in additional diagnostic tools as well as pharmacological brain structure targets.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by CAPES, CNPq, FAPESP and FAPERGS
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Summary statistic data directions can be found in Zhao et al. (2021) and Demontis et al. (2019)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
